Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. (Q53968585)

23 May 2018

title

Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. (English)

1 reference

23 May 2018

1 reference

Neuvonen PJ

1

1 reference

23 May 2018

Kantola T

series ordinal

2

1 reference

23 May 2018

Kivistö KT

series ordinal

3

1 reference

23 May 2018

language of work or name

English

0 references

publication date

1 March 1998

1 reference

23 May 2018

Clinical Pharmacology & Therapeutics

published in

1 reference

23 May 2018

volume

63

1 reference

23 May 2018

issue

3

1 reference

23 May 2018

page(s)

332-341

1 reference

23 May 2018

Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990165-5

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990165-5

Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990165-5

Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990165-5

Drug-interaction-induced rhabdomyolysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990165-5

Coadministration of itraconazole with hypolipidemic agents may induce rhabdomyolysis in healthy individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990165-5

Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990165-5

Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990165-5

Biotransformation of lovastatin. IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990165-5

Pravastatin. A reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990165-5

Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990165-5

Determination of the HMG-CoA reductase inhibitors simvastatin, lovastatin, and pravastatin in plasma by gas chromatography/chemical ionization mass spectrometry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990165-5

Determination of pravastatin sodium and its major metabolites in human serum/plasma by capillary gas chromatography/negative ion chemical ionization mass spectrometry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990165-5

Comparative pharmacokinetics of lovastatin, simvastatin and pravastatin in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990165-5

Determination of itraconazole in serum with high-performance liquid chromatography and fluorescence detection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990165-5

CYP3A gene expression in human gut epithelium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990165-5

Biotransformation of pravastatin sodium (I). Mechanisms of enzymic transformation and epimerization of an allylic hydroxy group of pravastatin sodium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990165-5

Metabolism of pravastatin sodium in isolated rat hepatocytes. I. Glutathione conjugate formation reaction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990165-5

In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990165-5

10.1016/S0009-9236(98)90165-5

7 January 2021

Identifiers

DOI

1 reference

23 May 2018

release_qsytufbfkbejphobywdsurioxy

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/qsytufbfkbejphobywdsurioxy

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

23 May 2018